Drug news

Vestiq Pharma licenses Oravig for Oropharyngeal Candidiasis in US from BioAlliance Pharma

Read time: 1 mins

Last updated:23rd Jul 2012

Published:23rd Jul 2012

Source: Pharmawand

BioAlliance Pharma has entered into a licence agreement with Vestiq Pharmaceuticals, under which the latter gains the US commercialisation rights to the antifungal treatment, Oravig (miconazole), for oropharyngeal candidiasis in adults.Following PAR Strativa restructuring and change of its strategy including the acquisition of generic portfolio, BioAlliance Pharma had decided to regain full US commercialisation rights for Oravig in October 2011.In Europe, the product is marketed as Loramyc by the Therabel Group.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Safety of switching from a Vitamin K antagonist to a non–Vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation.

FRAIL-AF trial investigators set out to study the question of whether frail, elderly patients with atrial fibrillation who were doing well with vitamin K antagonists (VKA) should be switched to direct-acting oral anticoagulants (DOAC).

1 mins

Drug news

FDA approves updated Lupkynis (voclosporin) label to include long term data from the Aurora Clinical Program.-- Aurinia Pharmaceuticals.

Aurinia Pharmaceuticals Inc. announced that the FDA has approved a label update for Lupkynis. The updated label no longer includes language indicating that the safety and efficacy of Lupkynis has not been established beyond one year.

3 min

Drug news

Phase III KEYNOTE-811 trial met dual primary endpoint of overall survival (OS) as first-line treatment in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.- Merck Inc.,

Merck Inc., known as MSD outside of the United States and Canada, announced that the Phase III KEYNOTE-811 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with trastuzumab and fluoropyrimidine- and platinum-containing chemotherapy met its dual primary endpoint of overall survival (OS) for the first-line treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

1 min

See all news